U. S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Amendment #1)
(Mark One)
|
[X]
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the fiscal year ended December 31, 2015
|
[ ]
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from ___________ to _____________
Commission File Number: 000-54296
AXIM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
Nevada
|
27-4092986
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
18 East 50th Street, 5th Floor
New York, NY 10022
______________________________________________________________
(Address of principal executive offices, including zip code)
|
|
Registrant's telephone number, including area code: (212) 751-0001
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act: Common stock, $.0001 par value
___________________
Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. No [ X ]
Indicate by check mark whether the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. No [ X ]
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. No [X]
Indicate by check mark if the registrant is not required to file report pursuant to Section 13 or Section 15(d) of the Act. Yes [X]
Note - Checking in the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act form their obligations under those Sections.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X]
Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment of this Form 10-K. No [X]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule12b-2 of the Exchange Act.
|
Large accelerated filer [ ]
|
Accelerated filer [ ]
|
Non-accelerated filer [ ]
(Do not check if smaller reporting company)
|
Smaller reporting company [X]
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). No [ X ]
State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed fiscal quarter: $37,000,000 based upon the June 30, 2015 closing price as quoted on Yahoo/Finance.com.
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant filed all documents and reports required to be filed by Section 12, 13, or 15(d) of the Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court. Yes [ ] No [ ]
(APPLICABLE ONLY TO CORPORATE REGISTRANTS)
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: As of April 13, 2016, there were 39,762,659 shares of our common stock were issued and outstanding.
DOCUMENTS INCORPORATE BY REFERENCE: None
EXPLANATORY NOTE
The sole purpose of this Amendment No. 1 to the Annual Report on Form 10-K (the "Form 10-K") for the Year ended December 31, 2015, is to furnish Exhibit 101 to the Form 10-K in accordance with Rule 405 of Regulation S-T. Exhibit 101 to the Form 10-K provides the financial statements and related notes from the Form 10-K formatted in XBRL (eXtensible Business Reporting Language). No other changes have been made to the Form 10-K. This Amendment No. 1 to the Form 10-K speaks as of the original filing date of the Form 10-K, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-K. Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
Item 15. Exhibits, Financial Statement Schedules.
|
Statements
|
||||
|
Report of Independent Registered Public Accounting Firm - RBSM, LLP
|
||||
|
Consolidated Balance Sheets as of December 31, 2015 and 2014
|
||||
|
Consolidated Statements of Operations for the years ended December 31, 2015 and 2014
|
||||
|
Consolidated Statements of Changes in Shareholders' Deficit for the years ended December 31, 2015 and 2014
|
||||
|
Consolidated Statements of Cash Flows for the years ended December 31, 2015 and 2014
|
||||
|
Notes to Consolidated Financial Statements
|
||||
|
Schedules
|
||||
|
All schedules are omitted because they are not applicable or the required information is shown in the Financial Statements or notes thereto.
|
||||
|
Exhibit
|
Incorporated by Reference
|
Filing
|
Filed with
|
|
|
Exhibits
|
#
|
Form Type
|
Date
|
This Report
|
|
Articles of Incorporation, as filed with the Nevada Secretary of State on November 18, 2010.
|
3.1
|
10-Q
|
11/14/14
|
|
|
By-laws.
|
3.2
|
10-Q
|
11/14/14
|
|
|
Certificate of Amendment, as filed with the Nevada Secretary of State on July 24, 2014.
|
3.3
|
10-Q
|
11/14/14
|
|
|
Employment Agreement effective June 13, 2014, by and between the Company and Dr. George E. Anastassov.
|
10.1
|
10-K
|
4/14/15
|
|
|
Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended
|
31.1
|
X
|
||
|
Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d 14(a), promulgated under the Securities and Exchange Act of 1934, as amended
|
31.2
|
X
|
||
|
XBRL Instance Document
|
101.INS
|
X
|
||
|
XBRL Taxonomy Extension Schema Document
|
101.SCH
|
X
|
||
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
101.CAL
|
X
|
||
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.DEF
|
X
|
||
|
XBRL Taxonomy Extension Label Linkbase Document
|
101.LAB
|
X
|
||
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
101.PRE
|
X
|
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
AXIM BIOTECHNOLOGIES, INC.
/s/ Dr. George E. Anastassov
By: Dr. George E. Anastassov
Its: Chief Financial Officer
Its: Principal Accounting Officer
In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant on the capacities and on the dates indicated.
|
Signatures
|
Title
|
Date
|
|
/s/ Dr. George E. Anastassov
Dr. George E. Anastassov
|
Chairman
|
April 15, 2016
|
|
/s/ Dr. Philip A. Van Damme
Dr. Philip A. Van Damme
|
Director
|
April 15, 2016
|
|
/s/ Lekhram Changoer
Lekhram Changoer
|
Director
|
April 15, 2016
|